Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal-Reference-Cited by-同舟云学术

Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal

Published:2019-01-04 Issue:1 Volume:3 Page:24-26
ISSN:2474-252X
Container-title:Clinical Practice and Cases in Emergency Medicine
language:
Short-container-title:

Author:

Overbeek Daniel¹,Abraham Jonathan¹,Munzer Brendan¹

Affiliation:

1. University of Michigan, Department of Emergency Medicine, Ann Arbor, Michigan

Abstract

Kratom (mitragynine) is a naturally occurring opioid agonist whose use has been escalating. Its suppliers advertise it as a safe alternative for opioids and a safe treatment for opioid-withdrawal symptoms. There has been controversy in the past two years regarding the legal status and lack of regulation surrounding kratom. Currently, kratom is legal and unregulated, leaving users at risk from unpredictable potencies and effects. We present the first case of successful naloxone reversal of opioid toxidrome from recreationally used kratom. We advocate further research and regulation to ensure standardized dosing to protect patients.

Publisher

Western Journal of Emergency Medicine

Subject

General Medicine

Reference17 articles.

1. Rook W. The Addictions Coach: Kratom for Opiate Withdrawal. What is it and How Does it Work? Guest blog from author, Wendi Rook. 2015. Available at: https://theaddictionscoach.com/the-addictions-coach-kratom-for-opiate-withdrawal-what-is-it-and-how-does-it-work-guest-blog-from-author-wendi-rook/. Accessed April 4, 2018.

2. Stetzel K. The FDA Is Still Trying to Ban Kratom, a Potential Solution to the Opioid Epidemic. Reason. 2018. Available at: https://reason.com/blog/2018/02/12/fda-declares-kratom-an-opioid. Accessed June 24, 2018.

3. Gianutsos GPJ. The DEA changes its mind on kratom. US Pharmacist. 2017. Available at: https://www.uspharmacist.com/article/the-dea-changes-its-mind-on-kratom. Accessed April 4, 2018.

4. Cumpston KL, Carter M, Wills BK. Clinical outcomes after kratom exposures: Aapoison center case series. Am J Emerg Med. 2018;36(1):166-8.

5. McIntyre IM, Trochta A, Stolberg S, et al. Mitragynine ‘kratom’ related fatality: a case report with postmortem concentrations. J Anal Toxicol. 2015;39(2):152-5.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of kratom use and knowledge at a rural, Oregon community health center;Journal of the American Pharmacists Association;2024-09

2. An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations;Expert Review of Clinical Pharmacology;2024-01-22

3. Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy;Journal of Midwifery & Women's Health;2023-09-07

4. Cases: Multiorgan failure in a 38-year-old man with recent consumption of kratom, an atypical opioid;Psychiatry Research Case Reports;2023-06

5. Forensic Implications of Kratom: Kratom Toxicity, Correlation with Mitragynine Concentrations, and Polypharmacy;Current Addiction Reports;2023-05-19